86 FIGURE 40 : TEMPS, p.88 ,
de l'aspirine (300 mg/kg en dose unique), du clopidogrel (75 mg/kg/j pendant 5 jours) et le mononitrate d'isosorbide ,
Nicox signe un contrat de licence exclusif avec Fera Pharmaceuticals pour le développement et la commercialisation du naproxcinod aux Etats-Unis. Fera pharmaceuticals se concentre sur le traitement des signes et symptômes de l'arthrose. Des travaux supplémentaires devront être requis avant de soumettre à nouveau un dossier de New Drug Application, 2015. ,
Role of nitric oxide and other endothelium-derived factors, Medicina, pp.39-43, 2003. ,
Nitric oxide pathway and female lower urinary tract. Physiological and pathophysiological role, J Assoc Fr Urol, vol.23, issue.11, pp.926-935, 2013. ,
URL : https://hal.archives-ouvertes.fr/inserm-01015446
Rapport IST : le monoxyde d'azote. Universite?deUniversite?de Versailles Saint Quentin en Yvelines, 2003. ,
Nitric oxide and peroxynitrite in health and disease, Physiol Rev, vol.87, issue.1, pp.315-424, 2007. ,
Inhaled nitric oxide and persistent pulmonary hypertension of the new born, New Engl J Med, vol.6, pp.336-605, 1997. ,
Nitric Oxide: physiology et pharmacology, Anesth Analg, vol.81, pp.1052-1059, 1995. ,
Les oxydes d'azote, 2006. ,
Arginine metabolism: nitric oxide and beyond, Biochem J, vol.336, pp.1-17, 1998. ,
Nitric oxide as a unique bioactive signaling messenger in physiology and pathophysiology, J Biomed Biotechnol, vol.4, pp.227-237, 2004. ,
Nitric oxide synthases: structure, function and inhibition, J Biochem, vol.357, pp.593-615, 2001. ,
Nitric oxide synthases: regulation and function ,
Nitric oxide signaling in plants : cross-talk with Ca2+ , protein kinases and reactive oxygen species, Annu Plant Rev, vol.42, pp.147-170, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-00425512
Regulation of nitric oxide-sensitive guanylyl cyclase ,
Rôle clinico-biologique du monoxyde d'azote.Thèse de Docteur de l, 2010. ,
Guanylyl cyclases and signaling by cyclic GMP, Pharmacol Rev, vol.523, pp.375-414, 2000. ,
S-Nitrosothiols: a class of nitric oxide-donor drugs, Clinical sc, pp.98-507, 2000. ,
Endogenous regulation of human Schlemm's canal cell volume by nitric oxide signaling, Invest Ophthalmol Vis Sci, issue.11, pp.51-5817, 2010. ,
Hypertension artérielle pulmonaire persistante du nouveau-né et monoxyde d'azote : de la physiologie a la thérapeutique, J Pédiatr Puériculture, vol.10, issue.4, pp.195-199, 1997. ,
Le monoxyde d'azote inhalé : un traitement plus physiologique de l'hypertension artérielle pulmonaire persistante du nouveau-né, Arch Pédiatr, vol.4, pp.988-1003, 1997. ,
Circulation foetale et postnatal. [en ligne] Site disponible sur ,
Hypertension pulmonaire de l'enfant et du nouveau-né en réanimation ,
Persistent pulmonary hypertension of the newborn: recent advances in pathophysiology and treatment, J Pediatr, vol.893, pp.226-242, 2013. ,
Actualités thérapeutiques dans l'hypertension artérielle pulmonaire persistante du nouveau-né, Rev Med Liege, vol.62, pp.5-6, 2007. ,
Commission de la transparence, 2014. ,
nitric oxide) for inhalation, 2011. ,
Nitric oxide delivery system, Brevet US, vol.5558083, pp.24-33 ,
Which future in cardiovascular therapy for nitric oxide and its derivatives?, Ann Pharm Fr, pp.71-84, 2013. ,
URL : https://hal.archives-ouvertes.fr/hal-01291781
est ce que la schizophre?nischizophre?ni ?Fondation fondamental Réseau de coopération scientifique en santé mentale, 2015. ,
Sodium nitroprusside, a nitric oxide donor for novel treatment of schizophrenia, may also modulate dopaminergic systems, Schizophr Res, vol.159, pp.2-3, 2014. ,
Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: a randomized, double-blind, placebo-controlled trial, JAMA Psychiatry, vol.7, pp.70-668, 2013. ,
Commission de la transparence, 2012. ,
Commission de la transparence, p.3, 2012. ,
Commission de la transparence, 2012. ,
Commission de la transparence, 2007. ,
Commission de la transparence, 2015. ,
Recent developments in the effects of nitric oxide-donating ,
NCX 6560, a nitric oxidereleasing derivative of atorvastatin, inhibits cholesterol biosynthesis and shows antiinflammatory and anti-thrombotic properties, Eur J Pharmacol, vol.570, pp.1-3, 2007. ,
Anatomie et physiologie de l'oeil, 2015, 2016. ,
Site disponible sur :<www.leglaucome.fr> ,
Alterations of ocular nitric oxide synthase in human glaucoma, Invest Ophthalmol Vis Sci, vol.36, issue.9, pp.1774-1784, 1995. ,
Identification of an extensive system of nitric oxide-producing cells in the ciliary muscle and outflow pathway of the human eye ,
eNOS, a pressuredependent regulator of intraocular pressure, Invest Ophthalmol Vis Sci, vol.13, pp.52-9438, 2011. ,
Étude comparant la sécurité et l'efficacité de BOL-303259-X au latanoprost chez des sujets atteints de glaucome ou d'hypertension oculaire ,
A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study, Br J Ophthalmol, vol.6, pp.99-738, 2015. ,
A prospective randomized, multicenter, single-masked, parallel, dose ranging (voyager) Study to compare the safety and efficacy of BOL-303259-X to latanoporst in subjects with open angle glaucoma or ocular hypertension, Am Glaucoma Soc, vol.23, issue.19 ,
Novel glaucoma drug rivals standard therapy. [en ligne] Site disponible sur <http://ophthalmologytimes.modernmedicine.com/ophthalmologytimes/news/novelglaucoma-drug-rivals-standard-therapy#> ,
Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension (LUNAR). [en ligne] Site disponible sur <http://clinicaltrials.gov/show, p.1749930 ,
Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension (APOLLO) ,
A Study Evaluating the Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024%, in Japanese Subjects With Open-Angle Glaucoma or Ocular Hypertension (JUPITER). [en ligne] Site disponible sur : <http://clinicaltrials.gov/show, p.1895972 ,
La prise en charge dans la dystrophie musculaire de Duchenne, Orphanet, 2009. ,
Nicox reçoit une opinion positive pour le naproxcinod sur la désignation de médicament orphelin en Europe dans la Dystrophie Musculaire de Duchenne, 2016. ,
Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy, Proc Natl Acad Sci, vol.104, issue.1, pp.264-249, 2007. ,
Use of nitrooxyderivative of drug for the treatment of muscular dystropphies ,
Muscular nitric oxide synthase (muNOS) and utrophin, J Physiol, vol.96, pp.1-2, 2002. ,
URL : https://hal.archives-ouvertes.fr/hal-00171305
Naproxcinod, a nitric oxidedonating anti-inflammatory compound, is effective in two mouse models of muscle dystrophy, Neuromuscul Disord, vol.23, pp.9-10, 2013. ,
Long term treatment with naproxcinod significantly improves skeletal and cardiac function in mdx mouse model of dystrophy, Neuromuscul Disord, vol.201323, pp.9-10799 ,
The serum nitric oxide levels in patients with Duchenne muscular dystrophy, Brain Dev, vol.223, pp.181-183, 2000. ,
Résultats précliniques pour le naproxcinod sur des modèles de dystrophie musculaire présentés à la MDA Scientific Conference, 2016. ,